NCT05603052View on ClinicalTrials.gov

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

2,852

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

EuCorVac-19

COVID-19 vaccine

BIOLOGICAL

ChAdOx1 nCoV-19

COVID-19 vaccine

Trial Locations (1)

Unknown

Trial site, Kinshasa

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT05603052 - A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older | Biotech Hunter | Biotech Hunter